Systagenix Wound Management Introduced as a New Force in Wound Care

   Systagenix Wound Management (London) is a new portfolio company created by One Equity Partners (New York, NY) that was recently launched with the intent of establishing a new global force in advanced wound care.

   Systagenix Wound Management is formerly the professional wound care business of Ethicon Inc, a Johnson & Johnson company (Somerville, NJ). The new company will focus on achieving further success, while building on its internationally renowned advanced and general wound care product portfolios. These portfolios include brands such as Promogran® Matrix Wound Dressing, Tielle® Hydropolymer Dressing, and Regranex® (becaplermin) gel 0.01%, a prescription treatment for lower extremity diabetic foot ulcers.

   The new company will be headquartered in the United Kingdom, including a manufacturing and Research and Development facility based in Gargrave, North Yorkshire.

   Call +44 (0) 207-498-8211 for more information.

ConvaTec Appoints Presidents of Wound Therapeutics and Ostomy Care Business Units

   ConvaTec (Skillman, NJ) announced that Michael E. Steadman will become President of ConvaTec’s Wound Therapeutics Business Unit and Nino Pionati has been appointed as President of the Ostomy Care Business Unit.

   Stedman joins ConvaTec from DFB Pharmaceuticals Inc where he was Group President and Chief Operating Officer. He also previously served as President of Healthpoint Ltd. Pionati has been with ConvaTec since 1998 and most recently served as Senior Vice President of Global Marketing & Business Development.

   Following the acquisition of Copenhagen-based Unomedical in September, ConvaTec had announced the formation of four new operating divisions: Ostomy Care, Wound Therapeutics, Continence and Critical Care, and Infusion Devices.

   Visit http://www.convatec.com for more information.

Wound Management Technologies’ Collagen-based Product Receives 510k Clearance

   Wound Care Innovations LLC (Fort Worth, Tex), a subsidiary of Wound Management Technologies Inc, received 510k clearance of a new wound management product utilizing their patented hydrolyzed collagen technology.

   The product combines hydrolyzed collagen with the healing properties of polysulfated glycosaminoglycan (PSGAG) and will initially be available in gel form. Polysulfated glycosaminoglycan enhances the absorptive capacity of the hydrolyzed collagen gel, making it appropriate for the management of exudative wounds. PSGAG has been shown to prepare the granulation tissue for epidermal migration by maintaining a uniform, low-density granulation tissue more easily modified by the migrating epithelium, therefore improving the rate of epithelialization of a chronic wound and reducing scarring.

   The product has been cleared and is indicated for topical use in the management of chronic and acute wounds. The gel is also intended for dermal ulcers including the management of pressure ulcers (Stages I–IV), venous stasis ulcers, diabetic ulcers, first and second degree burns, surgical wounds, traumatic wounds, superficial wounds, ulcers resulting from arterial insufficiency, and grafted wounds and donor sites.

   Visit http://www.celleraterx.com for more information.

XTL Biopharmaceuticals Announces Completion of Phase 2b Study

   XTL Biopharmaceuticals Ltd (Valley Cottage, NY) announced that the last patient randomized into the Bicifadine Phase 2b clinical trial for the treatment of diabetic neuropathic pain has completed the study.